Artal Group S.A. Curis Inc Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$7.45 - $16.27 $3.76 Million - $8.21 Million	-504,729 Reduced 27.97%	1,300,000 $10.5 Million
Q4 2020 Feb 11, 2021	BUY	$1.08 - $8.2 $432,000 - $3.28 Million	400,000 Added 28.48%	1,804,729 $14.8 Million
Q3 2020 Nov 13, 2020	SELL	$0.95 - $1.42 $70,236 - $104,984	-73,933 Reduced 5.0%	1,404,729 $1.64 Million
Q2 2020 Aug 14, 2020	SELL	$0.63 - $1.7 $13,442 - $36,274	-21,338 Reduced 1.42%	1,478,662 $1.79 Million
Q4 2019 Feb 13, 2020	BUY	$1.36 - $2.44 $2.04 Million - $3.66 Million	1,500,000 New	1,500,000 $2.55 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.